Storys zum Thema Chemie

Norgine

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...

pekutherm Kunststoffe GmbH

Pekutherm Positioned for Success in 2025

Pekutherm Positioned for Success in 2025 - Pekutherm Kunststoffe GmbH has embodied sustainability from the very beginning. - As a partner of the Europe-wide Recycling Alliance founded by Röhm, Pekutherm makes an important contribution to the circular economy. - Pekutherm is expanding its recycling capacity and strengthening its presence in European markets to meet growing demand. - Through recycling partnerships such as ...

GEA Group Aktiengesellschaft

More sustainable fuels: GEA wins first customer for Pre2Fuel process

Aurubis AG

Press release: Symbolic start of industrial heat feed-in to Hamburg city network

Norgine

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...

EU4Regions

2

5

Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality

LAUDA DR. R. WOBSER GMBH & CO. KG

Antonio Manconi Ten Years With LAUDA Italia

nova-Institut GmbH

6

Transforming CO₂ into Opportunities: The CO₂-Based Fuels and Chemicals Conference 2025

Obrist Group

Obrist Anticipates a Pivotal Shift Towards "Liquid Solar Energy" in 2025

Gerresheimer AG

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Accord Healthcare

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...

Obrist Group

Obrist Group Introduces Alternatives to PFAS and F-Gases

Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...

Technische Universität München

Removing hazardous PFAS chemicals from drinking water

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM researchers develop highly effective filter material Removing hazardous PFAS chemicals from drinking water - Metal-organic framework compounds made of zirconium carboxylate as filters - Large-scale use in practice still to come - Contaminated sites caused by PFAS will be with us for several generations ahead The chemicals known as PFAS are considered a severe threat to ...

Obrist Group

Obrist Group: Methanol as the Ideal Fossil Fuel Replacement for Key Industries

Strides Pharma International AG

Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

nova-Institut GmbH

6

Capture, Convert, and Conquer: Innovations Wanted for the “Best CO₂ Utilisation 2025” Innovation Award

Aurubis AG

Press release: Aurubis investing € 40 million in more independent and efficient production in Lünen

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

LAUDA DR. R. WOBSER GMBH & CO. KG

40th work anniversary at the world market leader

nova-Institut GmbH

5

Advanced Recycling Conference 2024 – Driving Innovation in Sustainable Materials Management

Technische Universität München

Significant Extension of Zinc Battery Lifespan

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE TUM Researchers Develop New Chemical Method for Improved Energy Storage Significant Extension of Zinc Battery Lifespan - Improvement to several hundred thousand charge cycles - Protective layer for zinc anode - Important result in basic research - Large-scale engineering implementation still pending The transition to renewable energy requires efficient methods for storing large ...

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

Obrist Group

Obrist Group: Modern Forest is 30 Times Better for the Climate Than Traditional Forests

hubergroup Deutschland GmbH

4

Press Release - hubergroup showcases Innovative Solutions at EURASIA PACKAGING FAIR 2024